Meeting
2015 ASCO Annual Meeting
Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM).
Authors
Roxana Stefania Dronca
Mayo Clinic, Rochester, MN
Roxana Stefania Dronca , Svetomir Markovic , Lisa A. Kottschade , Robert R. McWilliams , Matthew Stephen Block , Wendy Kay Nevala , Michael A Thompson , Haidong Dong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9013)
DOI
10.1200/jco.2015.33.15_suppl.9013
Abstract #
9013
Poster Bd #
256
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical value of noninvasive biomarkers reflecting a collagen-rich stroma in metastatic melanoma patients treated with anti-PD1 therapy.
First Author: Christina Jensen
Poster
2018 ASCO Annual Meeting
Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
First Author: Hussein Abdul-Hassan Tawbi
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).
First Author: Yada Kanjanapan
Poster
2020 ASCO Virtual Scientific Program
High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.
First Author: Jorge D. Oldan